Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active Ankylosing Spondylitis (AS)

NCT07498634 is registered in ClinicalTrials.gov with Zhejiang Kanova Biopharmaceutical Co., LTD as lead sponsor.

NCT NCT07498634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07498634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active Ankylosing Spondylitis (AS)
Lead sponsor
Zhejiang Kanova Biopharmaceutical Co., LTD
Phase
Phase 3
Overall status
Completed
Start date
September 21, 2023
Completion date
November 14, 2025
Enrollment
323 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

phase iii